The annual inflation rate in New Zealand accelerated to 7.3%, a new high since 1990 and above average forecasts for 7.1%. The quarterly price growth of 1.7% also remains elevated, showing no deceleration in the Read more…
Outlook. We lower our GDP forecast for 2022 to 2.7% (from 3.7%) while keeping the 5.7% forecast for 2023. The economy recovered in June in a post-lockdown rebound. However, China is facing renewed headwinds from Read more…
General Electric stock has clear support and resistance on the chart. The question is: Which one will break first? General Electric (GE) – Get General Electric Company Report stock is rallying on July 18, up about Read more…
Summary The FOMC appears poised to raise its target range for the federal funds rate by at least 75 bps at its next meeting on July 27. The 372K increase in nonfarm payrolls in June Read more…
Spot gold edges higher on Monday after hitting the lowest in almost one year last week, being deflated by rising dollar on expectations of aggressive Fed in its July policy meeting. The US central bank Read more…
The dollar has skyrocketed over the past 12 months, partly as the Federal Reserve boosted interest rates. The dollar has been on fire over the past year, with the WSJ Dollar Index touching a 20-year Read more…
The most popular cryptocurrency exchange in the U.S. faces declining trading volumes. This is news that will undoubtedly do Coinbase (COIN) – Get Coinbase Global Inc Report a lot of good. For several months, the most Read more…
Use this option strategy to trade earnings when the implied move is smaller than average! Here’s a way to play earnings by comparing the historic average earnings move of a stock to the current implied Read more…
In an effort to tame soaring prices across the eurozone, the ECB is prepping to raise interest rates. What impact will a rising rate environment have on Europe’s debt situation? Is the eurozone headed for Read more…
It has one product on the market and up to four more launching by the end of 2023. The growth trajectory depends on execution. Many investors have probably never heard of Coherus BioSciences (CHRS) – Read more…